EC Number   |
Title |
Organism |
|---|
   2.7.10.1 | Development of potent inhibitors of receptor tyrosine kinases by ligand-based drug design and target-biased phenotypic screening |
Homo sapiens |
| 2.7.10.1 | Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3) |
Homo sapiens |
| 2.7.10.1 | High levels of receptor tyrosine kinases in ccm3-deficient cells increase their susceptibility to tyrosine kinase inhibition |
Homo sapiens |
| 2.7.10.1 | Mechanism of Mer receptor tyrosine kinase inhibition of glomerular endothelial cell inflammation |
Mus musculus |
| 2.7.10.1 | Monitoring activities of receptor tyrosine kinases using a universal adapter in genetically encoded split TEV assays |
Homo sapiens |
| 2.7.10.1 | Receptor tyrosine kinase signaling networks define sensitivity to ERBB inhibition and stratify KRAS-mutant lung cancers |
Homo sapiens |
| 2.7.10.1 | RET functions as a dual-specificity kinase that requires allosteric inputs from juxtamembrane elements |
Homo sapiens |
| 2.7.10.1 | Synthesis and in vitro cytotoxicity of the 4-(halogenoanilino)-6-bromoquinazolines and their 6-(4-fluorophenyl) substituted derivatives as potential inhibitors of epidermal growth factor receptor tyrosine kinase |
Homo sapiens |
| 2.7.10.1 | 4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase |
Homo sapiens |
| 2.7.10.1 | 4-Substituted quinazoline derivatives as novel EphA2 receptor tyrosine kinase inhibitors |
Homo sapiens |
